Amniotics’ COO invited speaker at global ATMP congress

News

May 15, 2023

Amniotics AB (publ) (Nasdaq Stockholm: AMNI) today announces that the company Chief Operating Officer (COO), Jan Talts will speak at the “4th Global Bioprocessing, Bioanalytics & ATMP Manufacturing Congress”, taking place in Dublin 15-16 May 2023.

The title of the talk is “Biological raw material sourcing for an early stage ATMP and considerations for later clinical stage development”. This conference provides an interactive networking forum for bioprocessing experts to examine novel solutions and strategies that will improve the efficiency of biotherapeutic development.

About Amnioitics

Amniotics AB (publ) is a clinical stage biotech company, developing innovative therapies, based on amniotic fluid derived stem cells. The company develops therapies to treat diseases where effective treatments are currently lacking.
Amniotics has an established GMP-facility, approved and licensed by the Swedish Medical Products Agency. The company has capabilities as a Contract Development and Manufacturing Organization (CDMO) for other biotech companies.
Amniotics is headquartered in Lund, Sweden.
The company is listed at Nasdaq First North Growth Market in Stockholm. Amniotics Certified Adviser at First North is Redeye AB, e post: certifiedadviser@redeye.se.
Learn more at www.amniotics.com.

Amniotics’ COO invited speaker at global ATMP congress

Upcoming events

Subscribe